| Budget Amount *help |
¥23,790,000 (Direct Cost: ¥18,300,000、Indirect Cost: ¥5,490,000)
Fiscal Year 2016: ¥7,540,000 (Direct Cost: ¥5,800,000、Indirect Cost: ¥1,740,000)
Fiscal Year 2015: ¥7,410,000 (Direct Cost: ¥5,700,000、Indirect Cost: ¥1,710,000)
Fiscal Year 2014: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
|
|---|
| Outline of Final Research Achievements |
It is widely known that the imbalance between pathogenic T cells and regulatory T cells is involved in the pathogenesis of rheumatoid arthritis (RA), however, the fundamental treatment for RA has not been established. We previously reported that a novel pathogenic T cell subset which is converted from regulatory T cells exacerbated autoimmune arthritis, however its effector mechanism remained to be elucidated. Here, by genetic methods, we clarified the importance of the interaction between the pathogenic T cell subset and tissue resident-mesenchymal cells in the bone destruction in arthritis. By comprehensive analysis, we identified several molecules that are specifically expressed in the new pathogenic T cell subset, which will contribute to the development of novel therapeutic strategies for rheumatoid arthritis in the future.
|
